LLY
50
3
INTU
65
5
NWSA
49
2
VFC
53
-4
ETR
66
-2
AIG
53
2
HRB
73
3
WDC
52
3
BEN
48
2
PEG
71
-3
LEN
64
3
EQIX
62
3
AVGO
49
9
CSX
64
4
WMT
63
-3
ED
49
-4
ILMN
44
2
CTAS
58
2
MOS
23
3
APA
28
3
LLY
50
3
INTU
65
5
NWSA
49
2
VFC
53
-4
ETR
66
-2
AIG
53
2
HRB
73
3
WDC
52
3
BEN
48
2
PEG
71
-3
LEN
64
3
EQIX
62
3
AVGO
49
9
CSX
64
4
WMT
63
-3
ED
49
-4
ILMN
44
2
CTAS
58
2
MOS
23
3
APA
28
3
Financhill
Back

Pacira BioSciences 10K Form

Sell
33

PCRX
Pacira BioSciences

Last Price:
14.71
Seasonality Move:
-2.82%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $674.98M
Cash Flow: $51.65M
Price / Cash Flow: 4.45
Annual Sales: $19.07
Price / Book: 0.77

Profitability

EPS (TTM): 1.33000
Net Income (TTM): $63.59M
Gross Margin: $490.31M
Return on Equity: 7.43%
Return on Assets: 4.03%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for PCRX is 72.64%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 39.92% of Gross Profit Margin.
  • The Research & Development expenses have been 11.30% of Revenue.
  • The Interest Expense is 41.26% of Operating Income.
  • The Net Earning history of PCRX is 6.22% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.67
Current Ratio: 6.82
Quick Ratio: 5.49

Price-to-Earnings

Trailing P/E Ratio: 16.51
Forward P/E Ratio: 4.86

PCRX Technical Analysis vs Fundamental Analysis

Sell
33
Pacira BioSciences (PCRX) is a Sell

Is Pacira BioSciences a Buy or a Sell?